Triple therapy enhances survival in advanced hepatocellular carcinoma.

In high-risk advanced hepatocellular carcinoma patients, triple therapy involving FOLFOX-based hepatic arterial infusion, tyrosine kinase inhibitors, and PD-1 inhibitors significantly improved median overall survival to 24.6 months compared to 11.9 months with dual therapy (HR=0.43, p<0.001). Progression-free survival also favored triple therapy at 10 months versus 7.7 months (HR=0.68, p=0.002). Additionally, more patients converted to non-high-risk status after triple therapy, indicating its potential as a first-line treatment.